Topics:

Genitourinary Cancers

Genitourinary Cancers

Preoperative levels of C-reactive protein may be as predictive of outcomes as pathological TNM stage or tumor grade for prognosis in renal cell carcinoma.

This article reviews the most recent advances in androgen receptor-directed therapies for castration-resistant prostate cancer, and new agents under development.

In the past 5 years we have taken at least 7 steps forward for men with prostate cancer—which hopefully will turn into “one giant leap” in our attempt to convert advanced prostate cancer into a chronic disease.

This is an exciting time for physicians who care for patients with advanced prostate cancer, and more importantly a time of heightened optimism for these men and their families.

It is now well established that castration-resistant disease can be effectively treated using newer androgen receptor-targeting agents such as abiraterone and enzalutamide.

A new study shows yet another link between increasing body mass index (BMI) and the risk of several common cancers, including kidney cancer.

A large European study found that PSA screening reduces prostate cancer deaths, but that these benefits do not outweigh the harms of overtreatment.

Pages

Subscribe to Genitourinary Cancers on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.